V. Janković

发表

AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.

Hui Zhao, Vladimir Jankovic, Ruud Delwel, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.

C. Allis, H. Erdjument-Bromage, P. Tempst, 2008, Genes & development.

mulatta): differential behavior of CD4 and CD8 subsets Phenotypic and functional T-cell aging in Rhesus Macaques (Macaca

I. Messaoudi, J. Nikolich-Žugich, V. Janković, 2013 .

Phenotypic and functional T-cell aging in rhesus macaques ( Macaca mulatta ) : differential behavior of CD 4 and CD 8 subsets

I. Messaoudi, J. Nikolich-Žugich, V. Janković, 2003 .

Phenotypic and functional T-cell aging in rhesus macaques (Macaca mulatta): differential behavior of CD4 and CD8 subsets.

I. Messaoudi, J. Nikolich-Žugich, V. Janković, 2003, Blood.

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype

L. Macdonald, A. Murphy, M. Ni, 2018, Science Immunology.

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

A. Rosenwald, S. Ansell, G. Yancopoulos, 2019, Hematological Oncology.

Human placenta-derived adherent cells induce tolerogenic immune responses

Wei Liu, S. Abbot, V. Janković, 2014, Clinical & translational immunology.

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

A. Chaudhry, R. Deering, J. Brouwer-Visser, 2022, British journal of haematology.

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

R. Advani, A. Dhanik, A. Chaudhry, 2020 .

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

R. Advani, A. Murphy, S. Ansell, 2019, Blood.

Cyclosporin A inhibits activation of inducible nitric oxide synthase in C6 glioma cell line

V. Badovinac, V. Trajković, V. Janković, 1999, Brain Research.

Human Placenta‐Derived Mesenchymal Stromal‐Like Cells Enhance Angiogenesis via T Cell‐Dependent Reprogramming of Macrophage Differentiation

Ivana M. Djuretic, M. Krakovsky, V. Janković, 2017, Stem cells.

Pentoxifylline inhibits the synthesis and IFN‐γ‐inducing activity of IL‐18

V. Trajković, D. Popadic, T. Samardžič, 2001 .

Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line.

V. Trajković, T. Samardžič, V. Janković, 2000, Immunology letters.

Cancer cell-derived type I interferons instruct tumor monocyte polarization.

G. Atwal, L. Macdonald, A. Murphy, 2022, Cell reports.

Modulation of Cell Attachment, Proliferation, and Angiogenesis by Decellularized, Dehydrated Human Amniotic Membrane in In Vitro Models.

R. Zaka, V. Janković, M. Bhatia, 2016, Wounds : a compendium of clinical research and practice.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Hedgehog signaling is dispensable for adult hematopoietic stem cell function.

R. Taichman, B. Kee, S. Nimer, 2009, Cell stem cell.

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

A. Hauschild, S. Puig, R. Dummer, 2021, The Lancet. Oncology.

Cyclin C Regulates Human Hematopoietic Stem/Progenitor Cell Quiescence

T. Naoe, S. Nimer, Yan Liu, 2009, Stem cells.

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

A. Hauschild, D. Schadendorf, I. Lowy, 2020, Journal for immunotherapy of cancer.

Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7

J. Zavadil, S. Nimer, I. Aifantis, 2008, The Journal of experimental medicine.

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

A. Hauschild, I. Lowy, R. Gutzmer, 2019, Journal of Clinical Oncology.

1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results

A. Hauschild, D. Schadendorf, N. Basset-Seguin, 2021, Annals of Oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

Meredith R. Legg, M. Merad, A. Kamphorst, 2022, The lancet. Gastroenterology & hepatology.

Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells

A. Ciarrocchi, R. Benezra, P. Boccuni, 2007, Proceedings of the National Academy of Sciences.

Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation

R. Kerbel, Y. Shaked, A. Ciarrocchi, 2007, PloS one.

Safety and efficacy of intramuscular human placenta‐derived mesenchymal stromal‐like cells (cenplacel [PDA‐002]) in patients who have a diabetic foot ulcer with peripheral arterial disease†

Stephanie Wu, Wei Zhou, R. Frykberg, 2017, International wound journal.

CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models

L. Havel, Fang Wang, A. Chaudhry, 2022, Science Translational Medicine.

T Cell Recognition of an Engineered MHC Class I Molecule: Implications for Peptide-Independent Alloreactivity1

A. Molano, J. Nikolich-Žugich, V. Janković, 2002, The Journal of Immunology.

Peptide-Independent Alloreactivity Class I Molecule: Implications for T Cell Recognition of an Engineered MHC

A. Molano, J. Nikolich-Žugich, V. Janković, 2002 .

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A. Chaudhry, J. Brouwer-Visser, M. Ufkin, 2020 .

STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts.

V. Trajković, T. Samardžič, V. Janković, 2001, Cytokine.

Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.

V. Trajković, D. Popadic, T. Samardžič, 2000, Cellular immunology.

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

I. Lowy, K. Papadopoulos, J. Crown, 2023, Journal of Clinical Oncology.

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

I. Lowy, O. Hamid, V. Janković, 2022, Annals of Oncology.